NEW JERSEY PAIN ATLAS · MANAGED CARE OVERSIGHT
The safety edit may ask the question. The number should not answer it.
NJ FamilyCare requires a 90 MME safety edit for established opioid tolerant therapy. The public contract describes greater risk, monitoring, and care coordination. It does not establish that the number alone should decide whether medically justified treatment continues.
The first move: require DMAHS to publish and compare the approved implementation standard used by all five managed care plans.
Primary public sources checked September 8, 2026. No plan is accused of automatic denial without the operative records.
01 · EXECUTIVE FINDING
New Jersey already owns the approval gate.
The current NJ FamilyCare managed care contract requires maximum daily MME safety edits for chronic pain opioid therapy. For an opioid tolerant individual, the state approved threshold is no more than 90 MME per day. Above that threshold, the contract describes high clinical risk and the value of closer monitoring and care coordination.
The same contract requires DMAHS review and approval of contractor drug utilization review policies, procedures, processes, standards, and revisions. New Jersey therefore has an administrative route for determining whether all five plans treat 90 MME as a review trigger or as a coverage ceiling.
The first question is factual: what happens in each plan after the edit fires?
02 · CLASSIFICATION METHOD
Preserve the difference between a screen and a decision.
- Safety edit: an electronic or administrative trigger that identifies a case for review.
- Clinical review: individualized evaluation of history, benefits, risks, response, and documented rationale.
- Coverage criterion: a standard used to approve, deny, reduce, or renew treatment.
- Override: the process for authorizing treatment when ordinary edit conditions are met.
- Continuity protection: a rule preventing disruption while review or appeal proceeds.
- Prescribing rule: a professional duty that is separate from Medicaid payment policy.
The contract proves that the edit exists. It does not by itself prove that any plan automatically denies established therapy above 90 MME. Production must come before accusation.
04 · NEW JERSEY’S OWN DISTINCTIONS
State law treats 90 MME as a point for added protection, not a prescribing ban.
New Jersey’s five day limit concerns an initial prescription for acute pain. Chronic pain is excluded from that acute pain definition and is governed by separate treatment plan, agreement, review, and risk management duties.
New Jersey law and the Board of Medical Examiners rule contemplate prescriptions above 90 MME and require an opioid antidote under stated conditions. The provisions reviewed for this Atlas do not impose a fixed 90 MME prescribing ceiling.
- Do not call the five day acute rule a chronic pain limit.
- Do not call 90 MME a statutory prescribing ceiling.
- Do not treat professional practice law as Medicaid coverage law.
- Do use the state’s risk mitigation response as a relevant policy analogue.
- Do verify the operative statute and rule before formal filing.
This does not decide Medicaid coverage. It shows why DMAHS should disclose whether its plans use the same number as a screen, a documentation trigger, or a final answer.
05 · THE EXACT REQUEST
Use DMAHS authority across all five plans.
DMAHS should publish the currently approved 90 MME implementation standard for every NJ FamilyCare managed care plan and confirm that the threshold triggers individualized review rather than deciding an adverse coverage result by itself.
- Produce the current DUR policy, clinical criteria, authorization criteria, renewal standard, and edit logic for each plan.
- Identify documentation requirements, rejection reasons, override authority, temporary supply rules, continuity protections, and appeal instructions.
- State whether exceeding 90 MME alone may support denial, reduction, discontinuation, or nonrenewal of established opioid tolerant chronic pain therapy.
- Identify the DMAHS approval date and revision history for each plan standard.
- Require a materially consistent minimum individualized review and continuity standard across all five plans.
- Publish aggregate outcomes and reason codes if those records are already maintained.
- Keep fee for service criteria in a separate record unless evidence establishes that the mechanism is identical.
06 · READY TO USE LANGUAGE
Ask DMAHS to identify the actual consequence.
Please provide or identify the currently approved 90 MME safety edit, drug utilization review standard, medical necessity criteria, override process, renewal standard, continuity procedure, and appeal route applicable to established opioid tolerant chronic pain therapy under each NJ FamilyCare managed care plan. Please state whether crossing 90 MME can itself support an adverse coverage result or whether an individualized clinical basis beyond the numerical threshold is required.
If any approved standard permits a dose alone determination, ask DMAHS to use its existing contract approval authority to require individualized review. If all five standards already provide that protection, publish the finding and close the principal issue.
07 · ACTION SEQUENCE
The records request comes first.
- Stage Zero: verify current personnel, plan names, contract version, and New Jersey governmental affairs requirements before targeted advocacy.
- Stage One: send the narrow DMAHS inquiry and request the five approved implementation standards.
- Stage Two: build a five plan comparison of trigger, evidence, decision maker, override, continuity, appeal, and DMAHS approval date.
- Stage Three: if the record shows inconsistency or a dose alone decision, place the exact defect before DMAHS and the DUR Board.
- Stage Four: examine fee for service only if its separate records show the same problem.
- Stage Five: preserve commissioners, executive offices, and legislation for a proven defect the administrative process does not correct.
Do not consume every escalation rung in the opening letter. A precise record gives each later recipient something concrete to decide.
08 · MEASURABLE RESULTS
The campaign ends when the rule is visible and consistent.
FIVE STANDARDS
The approved rule for every participating plan is publicly identifiable.
INDIVIDUAL REVIEW
Any adverse result states a clinical basis beyond the number itself.
REAL OVERRIDE
Evidence, decision authority, continuity, and appeal routes are disclosed.
STATE OVERSIGHT
DMAHS approval dates and required corrections are documented.
A favorable statement without synchronized criteria, contractor instructions, adjudication logic, and renewal procedures is not completion.
09 · THE FEDERAL BOUNDARY
Federal Medicaid law requires the edit and preserves individualized therapy.
42 C.F.R. § 456.703 requires prospective opioid safety edits addressing maximum daily MME. It also requires sufficient professional prerogatives for individualized drug therapy and requires predetermined standards to be clinically based, evaluated, modified, and publicly available after adoption.
New Jersey’s March 2024 DUR newsletter calls MME a practical guide for initial prescribing and reassessment. The page does not claim that the newsletter decides coverage. It provides an official state statement against using the number as a substitute for the clinical question.
Keep the safety screen. Require the actual decision to explain the patient.
10 · COMPLIANCE, ESCALATION, AND OFF RAMP
Act inside New Jersey’s rules and give the state an easy exit.
New Jersey regulates some compensated communications intended to influence executive action. Before an organizational or compensated advocacy campaign begins, determine with qualified New Jersey counsel or ELEC whether registration or reporting applies. Ordinary records gathering should not be mislabeled, but it is not a substitute for this review.
The reform request is stronger with one New Jersey clinician and one affected New Jersey resident who have reviewed and genuinely support it. Do not manufacture standing or publish private medical details to prove participation.
If the five approved standards already make 90 MME a review trigger with a meaningful override, publish that answer. If DMAHS corrects a demonstrated defect, verify the correction and stop escalating.
11 · PRIMARY SOURCES
The New Jersey record is unusually specific.
- NJ Medicaid and Managed Care
- Current NJ FamilyCare Managed Care Contract
- NJ FamilyCare Health Plans
- March 2024 DURB MME Newsletter
- DURB Educational Newsletters
- Board of Medical Examiners Pain Rule Language
- Annual Fee for Service Prior Authorization Metrics
- 42 C.F.R. § 456.703
Verification note: Official sources were checked September 8, 2026. Contract versions, personnel, plan names, filing requirements, and submission routes must be checked again before action.
12 · THE NEW JERSEY POSITION
Use the number to find the case. Then review the case.
New Jersey already possesses the contract authority, professional framework, clinical forum, and public record needed to answer the first question. It does not need a larger theory before it identifies what every plan actually does.
This is the Oklahoma method applied to New Jersey: isolate one decision, identify the office that controls it, obtain the operative record, request one measurable correction, and close the campaign when the evidence supports closure.